Shenzhen Haplox Biotechnology Co., Ltd. is a hi-tech enterprise whom devoted itself into R&D and clinical application in ultromicro tumor genetic inspection, and obtained ￥50 million A round financing recently with unclear investor. Before that it received ￥10 million angel financing from Beijing Grains Valley Venture Capital in Dec. 2015.

Established in Shenzhen in 2014, and located in the south plaza Yuanxing Sci-tech Building in North District of Nanshan Science Park, Haplox group composed of young overseas returnees scientists and domestic top scientific talents who engaging in genomics, molecular biology, medical science, bioinformatics, machine learning, big data excavating, etc. The company` s predecessor was Haplox Genomics, LLC setting up in US San Francisco in Aug. 2013, while the name of Haplox originated from Haplotype, Haplo and X (DNA double-coiled spiral structure) and the other meaning is all species implies colorful application in genomic scientific field.

The patent reagent self-developed by Haplox could capture the DNA section for different cancers precisely with 99% of success rate and higher uniformity in capture deepness. After the capturing, to use Haplox database creation and amplification to obtain plenty of DNA library then doing the high-flux sequencing to support the next step cancer analysis.

Haplox has received almost ￥10 million capital fund from national, province and city projects and applied almost 10 sets of patents in-and-out the country cooperating with many Three Top hospitals from Beijing, Hunan, Jiangxi, Jiangsu, Guangdong and initiated the first national large-scale cancer genomic sequencing project——CCSP, Chinese Cancer Sequencing Project.

CCSP is the first precision medicine project for large cancer in China, it started up with Haplox and Shenzhen People` s Hospital aiming at lung cancer, mammary cancer, colorectal cancer, gastric cancer and liver cancer to realizing 10,000 people` s cancer early screening, prognosis monitoring, individual pharmacy guidance and creating Chinese first genomic database for large cancer to laying foundations for precision medicine.

Dr. Xu Mingyan, CEO and founder of Haplox indicated that after A round financing finished, Haplox will focus on market promotion, enhance clinical transforming investment, advance the product developing quality and speed and increase customers service quality to benefit more consumers.